Subjects with subjective cognitive decline: 18F-Florbetaben Positrón Emission Tomography Study.

Trial Profile

Subjects with subjective cognitive decline: 18F-Florbetaben Positrón Emission Tomography Study.

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2017

At a glance

  • Drugs Florbetaben F18 (Primary)
  • Indications Cognition disorders
  • Focus Adverse reactions; Diagnostic use
  • Most Recent Events

    • 02 Nov 2017 Planned initiation date changed from 15 Mar 2017 to 1 Nov 2017.
    • 20 Feb 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top